Stay updated on Rituximab in Eosinophilic Granulomatosis Clinical Trial

Sign up to get notified when there's something new on the Rituximab in Eosinophilic Granulomatosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Rituximab in Eosinophilic Granulomatosis Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Revision: v3.5.2 is now displayed, replacing the previous v3.5.0.
    Difference
    0.1%
    Check dated 2026-04-16T10:14:26.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-25T20:29:03.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The study record now shows Completed status, the primary completion date, enrollment, and a new 2025 publication summarizing the results.
    Difference
    0.1%
    Check dated 2026-03-18T13:44:31.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    - Revision: v3.4.3 replaces v3.4.2 as the page framework version.
    Difference
    0.1%
    Check dated 2026-03-11T14:41:17.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed the funding-lapse notice and the previous Revision: v3.4.1 text.
    Difference
    0.4%
    Check dated 2026-02-11T01:36:08.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    Added a government funding lapse notice and open-status update, and updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-03T22:28:55.000Z thumbnail image

Stay in the know with updates to Rituximab in Eosinophilic Granulomatosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Rituximab in Eosinophilic Granulomatosis Clinical Trial page.